Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial
Cascone, T., William, W. N., Jr, Weissferdt, A., Leung, C. H., Lin, H. Y., Pataer, A., Godoy, M., Carter, B. W., Federico, L., Reuben, A., Khan, M., Dejima, H., Francisco-Cruz, A., Parra, E. R., Solis, L. M., Fujimoto, J., Tran, H. T., Kalhor, N., Fossella, F. V., Mott, F. E., … Sepesi, B. (2021). Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nature medicine, 27(3), 504–514. https://doi.org/10.1038/s41591-020-01224-2